What is the 13F Pro Quality Score for BDTX?

13F Pro ranks Black Diamond Therapeutics, Inc. (BDTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BDTX's current score at https://13fpro.ai/company/BDTX (free sign-up required for the full ranking).

Where does 13F Pro source BDTX data?

All Black Diamond Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Black Diamond Therapeutics, Inc. files with the SEC under CIK 1701541. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BDTX in?

Black Diamond Therapeutics, Inc. (BDTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BDTX research updated on 13F Pro?

BDTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Black Diamond Therapeutics, Inc.(BDTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1701541 BDTX stock profile & AI dashboard →

13F Pro Quality Score

37.2/100

Rank #2,228 of 3,064 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

100.0/100

Earnings Quality

46.3/100

Free Cash Flow

30.0/100

Institutional Flow

15.7/100

Revenue Scale

30.0/100

Dilution Risk

16.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BDTX Scores 37/100

exact factor attribution · 2026-08-23

BDTX's composite is driven by capital efficiency, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Capital efficiency

+5.0 pts

100th pct

Earnings quality

-0.4 pts

46th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-1.7 pts

16th pct

Institutional flow

-1.7 pts

16th pct

Profitability

-3.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Latest change (2026-08-05): 58 → 25 · ↓ Capital efficiency 96→6

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in BDTX

Events flagged as statistical outliers against BDTX's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-05
BDTX quality score dropped 33 points (58→25) on a new filing
View source filing →

BDTX Stock Analysis & AI Quality Score

Data updated 2026-08-23

AI stock analysis and institutional research for Black Diamond Therapeutics, Inc. (BDTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDTX at 37.2/100 on a 32-signal composite quality model, placing it at rank #2,228 of 3,064 stocks — the bottom half of the AI-ranked universe. BDTX scores in the top quartile across balance sheet strength (100.0). Areas of concern include institutional flow (15.7) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.3/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of BDTX by reported 13-F value include NEA Management Company, T. Rowe Price Investment Management, BlackRock, based on the most recent SEC filings. BDTX trades on the Nasdaq exchange and files with the SEC under CIK 1701541. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Black Diamond Therapeutics, Inc. directly from SEC EDGAR. Black Diamond Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 25 and 57 since 2026, currently 37.2 — an improving long-term trajectory across 25 quarterly and live scoring snapshots.

✦

Fun facts about Black Diamond Therapeutics, Inc.

Quirks, history, and lore behind BDTX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on oncology.
2
The Numbers
Like most clinical-stage biotechs, it carries no meaningful product revenue and burns cash on R&D — the balance sheet is essentially a countdown clock funded by equity raises.
3
The History
Founded around 2018, it was built on a scientific insight that most cancer drug programs had been targeting mutations the wrong way — chasing individual variants instead of the whole class.
4
The Secret
Its platform is called MAP — short for Mutation-Allostery-Pharmacology — designed to drug entire families of oncogenic mutations with a single compound rather than one mutation at a time.
5
The Lore
The company's name is a nod to its scientific ambition: targeting the hardest-to-reach, most stubborn mutations in cancer — the ones that, like a sheer rock face, everyone else said were unclimbable.
6
The Giveaway
Its ticker is BDTX, its lead programs target EGFR and RAS mutations, and its very name evokes the extreme sport of scaling black diamond-rated terrain — because curing cancer is not a bunny slope.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-9.9M

ROIC

Q2 2026

-50.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$70.0MFY 2025

FY22 —FY23 —FY24 $0.00FY25 $70.0M

Net Income

+132.1% YoY

$22.4MFY 2025

FY22 $-91.2MFY23 $-82.4MFY24 $-69.7MFY25 $22.4M

Operating Income

+115.9% YoY

$12.5MFY 2025

FY22 $-92.8MFY23 $-86.5MFY24 $-78.8MFY25 $12.5M

EPS (Diluted)

+130.7% YoY

$0.39FY 2025

FY22 $-2.52FY23 $-1.88FY24 $-1.27FY25 $0.39

Total Assets

+16.6% YoY

$143.0MFY 2025

FY22 $156.3MFY23 $158.6MFY24 $122.6MFY25 $143.0M

Op. Cash Flow

+147.5% YoY

$29.6MFY 2025

FY22 $-85.1MFY23 $-66.7MFY24 $-62.3MFY25 $29.6M

Free Cash Flow

—FY 2025

FY22 $-85.3MFY23 $-66.8MFY24 $-62.3MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$70.0M	$0.00	—	—	—	$0.00
Net Income	$22.4M +132.1%	$-69.7M +15.5%	$-82.4M +9.6%	$-91.2M +27.4%	$-125.6M -86.7%	$-67.3M
Operating Income	$12.5M +115.9%	$-78.8M +8.9%	$-86.5M +6.9%	$-92.8M +26.8%	$-126.9M -82.4%	$-69.6M
EPS (Diluted)	$0.39 +130.7%	$-1.27 +32.4%	$-1.88 +25.4%	$-2.52 +27.4%	$-3.47 -69.3%	$-2.05
Total Assets	$143.0M +16.6%	$122.6M -22.7%	$158.6M +1.5%	$156.3M -36.9%	$247.7M -24.9%	$329.7M
Operating Cash Flow	$29.6M +147.5%	$-62.3M +6.6%	$-66.7M +21.6%	$-85.1M +15.0%	$-100.1M -92.1%	$-52.1M
Free Cash Flow	—	$-62.3M +6.7%	$-66.8M +21.7%	$-85.3M +17.1%	$-102.9M -96.7%	$-52.3M

Get alerted when BDTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Black Diamond Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BDTX

NEA Management Company, LLC
$8.2M4,448,757 sh
T. Rowe Price Investment Management, Inc.
$7.5M4,028,202 sh
BlackRock, Inc.
$7.2M3,917,088 sh
ACADIAN ASSET MANAGEMENT LLC
$4.3M2,348,651 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.9M2,125,270 sh
RENAISSANCE TECHNOLOGIES LLC
$3.6M1,962,394 sh
Defilade Capital Management, L.P.
$3.1M1,674,999 sh
DIMENSIONAL FUND ADVISORS LP
$2.5M1,365,384 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.3M1,218,171 sh
Connor, Clark & Lunn Investment Management Ltd.
$2.0M1,092,885 sh

Fund	Value	Shares
NEA Management Company, LLC	$8.2M	4,448,757
T. Rowe Price Investment Management, Inc.	$7.5M	4,028,202
BlackRock, Inc.	$7.2M	3,917,088
ACADIAN ASSET MANAGEMENT LLC	$4.3M	2,348,651
VANGUARD CAPITAL MANAGEMENT LLC	$3.9M	2,125,270
RENAISSANCE TECHNOLOGIES LLC	$3.6M	1,962,394
Defilade Capital Management, L.P.	$3.1M	1,674,999
DIMENSIONAL FUND ADVISORS LP	$2.5M	1,365,384
GEODE CAPITAL MANAGEMENT, LLC	$2.3M	1,218,171
Connor, Clark & Lunn Investment Management Ltd.	$2.0M	1,092,885

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BDTX on your watchlist

Track score changes the day Black Diamond Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BDTX a good stock to buy?

13F Pro's AI-powered analysis of Black Diamond Therapeutics, Inc. (BDTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BDTX are available on the BDTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BDTX is classified as a small company.

Which hedge funds own BDTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BDTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Black Diamond Therapeutics, Inc.'s investment landscape.